Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.

@article{Abtan2016EfficacyAS,
  title={Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.},
  author={J{\'e}r{\'e}mie Abtan and Philippe G Steg and Gregg W. Stone and Kenneth W. Mahaffey and C Michael Gibson and Christian W. Hamm and Matthew J Price and Freddy Abnousi and Jayne Prats and Efthymios N. Deliargyris and Harvey D. White and Robert A. Harrington and Deepak L Bhatt},
  journal={JACC. Cardiovascular interventions},
  year={2016},
  volume={9 18},
  pages={
          1905-13
        }
}
OBJECTIVES The purpose of this study was to examine the safety and efficacy of cangrelor in patients with stable angina (SA) or acute coronary syndrome (ACS). BACKGROUND The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Cangrelor: Fixing Life or Just a Leak?

  • JACC. Cardiovascular interventions
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND